This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EDGE Edge Therapeutics (EDGE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock About Edge Therapeutics Stock (NASDAQ:EDGE) 30 days 90 days 365 days Advanced Chart Get Edge Therapeutics alerts:Sign Up Key Stats Today's Range$37.61▼$37.6150-Day Range$0.50▼$6.7152-Week Range$0.28▼$17.38Volume24 shsAverage Volume373,201 shsMarket Capitalization$1.19 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.Read More… Receive EDGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edge Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address EDGE Stock News HeadlinesSunflower Therapeutics Announces the First System Delivery and Installation of the Daisy Petal™ Perfusion Bioreactor System to BioBuilderMay 20 at 7:52 AM | finance.yahoo.comIntegra Therapeutics announces new pre-clinical data at 28th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT)May 14, 2025 | finance.yahoo.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.May 23, 2025 | Porter & Company (Ad)SEED Therapeutics Unveils Groundbreaking Advances in Cancer Research at AACR 2025May 9, 2025 | msn.com5VRDN : What 5 Analyst Ratings Have To Say About Viridian TherapeuticsMay 7, 2025 | benzinga.comUnited Therapeutics beats Q1 estimates, shares edge higherApril 30, 2025 | investing.comNutcracker Therapeutics CEO Dr. Igor Khandros Retires as Company Continues Evolution as an RNA Therapeutics CRDMOMarch 28, 2025 | finance.yahoo.comAlloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery PlatformFebruary 11, 2025 | businesswire.comSee More Headlines EDGE Stock Analysis - Frequently Asked Questions How were Edge Therapeutics' earnings last quarter? Edge Therapeutics, Inc. (NASDAQ:EDGE) announced its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.16. What other stocks do shareholders of Edge Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edge Therapeutics investors own include ContraFect (CFRX), McEwen Mining (MUX), Arena Pharmaceuticals (ARNA), BioLineRx (BLRX), Bristol-Myers Squibb (BMY), Cerecor (CERC) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings11/01/2018Today5/23/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EDGE CIK1472091 Webwww.edgetherapeutics.com Phone(800) 208-3343FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.29% Return on Assets-56.92% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book39.59Miscellaneous Outstanding Shares31,510,000Free FloatN/AMarket Cap$1.19 billion OptionableNot Optionable Beta3.65 Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:EDGE) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edge Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EDGE Stock Free EDGE Stock Alerts